<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630081</url>
  </required_header>
  <id_info>
    <org_study_id>W-4282-301</org_study_id>
    <nct_id>NCT03630081</nct_id>
  </id_info>
  <brief_title>Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace Finland OY</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, randomized, double-blind, multicenter, non-inferiority study to evaluate
      the efficacy, safety, and tolerability of FEP-TAZ vs. meropenem in the treatment of
      hospitalized adults with cUTI or AP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 1004 hospitalized adult subjects (≥18 years of age) diagnosed with cUTI or AP
      will be enrolled in the study. The diagnosis of cUTI or AP will be based on a combination of
      clinical symptoms and signs plus the presence of pyuria

      Subjects will be randomized in a 1:1 ratio according to an Interactive Response Technology
      (IRT) electronic system to receive either FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV
      every eight hours (q8h) or meropenem 1 g IV q8h. FEP-TAZ will be administered as 2
      consecutive infusions of 2 g (1 g cefepime + 1 g tazobactam)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 25, 2019</start_date>
  <completion_date type="Anticipated">December 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall success by clinical response by improvement in clinical symptoms e.g.fever</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall success by microbiological eradication by laboratory culture tests e.g bacterial load</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall safety will be based on incidence of number of TEAEs</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall safety will be based on incidence of number of abnormal electrocardiograms (ECGs) evaluations</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1004</enrollment>
  <condition>Complicated Urinary Tract Infection</condition>
  <condition>Acute Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>FEP-TAZ 4 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FEP-TAZ Pharmaceutical dosage form: Intravenous infusion Dosage: 4 g (2 g FEP and 2 g TAZ) IV q8h, infused over 90 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem Pharmaceutical dosage form: Intravenous infusion Dosage: 1 g IV q8h, infused over 45 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEP-TAZ 4 g</intervention_name>
    <description>4 g (2 g FEP and 2 g TAZ) IV q8h, infused over 90 min</description>
    <arm_group_label>FEP-TAZ 4 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>1 g IV q8h, infused over 45 min</description>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciprofloxacin 500 mg Optional Oral Switch</intervention_name>
    <description>ciprofloxacin 500 mg PO q12h</description>
    <arm_group_label>FEP-TAZ 4 g</arm_group_label>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Placebo infusion (normal saline) over 45 min</description>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Meet the following clinical criteria for either cUTI or AP:

        A. cUTI:

          1. Have at least TWO of the following new-onset or worsening symptoms or signs:

             Fever (oral, tympanic, or rectal temperature &gt;38°C [&gt;100.4°F]), which must be observed
             and documented by a health care provider Nausea or vomiting Dysuria, increased urinary
             frequency, or urinary urgency Lower abdominal, suprapubic, or pelvic pain

          2. Have at least ONE complicating factor

        B. AP, defined as acute flank pain (onset within 7 days prior to randomization) or
        costovertebral angle tenderness on physical examination, plus at least ONE of the following
        new-onset or worsening symptoms or signs:

        3. Evidence of pyuria within 48 h prior to randomization,

        Exclusion Criteria:

          1. Known or suspected disease or condition that, in the opinion of the investigator, may
             confound the assessment of efficacy.

          2. Receipt of potentially-effective systemic antibacterial therapy within 72 h prior to
             randomization

          3. Rapidly progressive or terminal illness with a high risk of mortality due to any
             cause, including but not limited to acute hepatic failure, respiratory failure, or
             septic shock, such that the subject is unlikely to survive the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashima Bhatia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wockhardt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manishkumar D Shah, PhD</last_name>
    <phone>91-22-26596893</phone>
    <email>Manish.Shah@wockhardt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mugdha A Gupta, MMS</last_name>
    <phone>91-22-26596892</phone>
    <email>mgupta@wockhardt.com</email>
  </overall_contact_backup>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

